Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in coronary atherosclerosis in type 2 diabetes
NCT03985384Phase 4Completed
- Sponsor
- The Lundquist Institute
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in coronary artery disease (CAD), sponsored by The Lundquist Institute. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03985384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985384.